In the absence of ACLY, cells upregulate ACSS2 and utilize exogenous acetate to provide acetylCoA for de novo lipogenesis (DNL) and histone acetylation. A physiological level of acetate is sufficient for cell viability and abundant acetyl-CoA production, although histone acetylation levels remain low in ACLY-deficient cells unless supplemented with high levels of acetate. ACLY-deficient adipocytes accumulate lipid in vivo, exhibit increased acetyl-CoA and malonyl-CoA production from acetate, and display some differences in fatty acid content and synthesis. Together, these data indicate that engagement of acetate metabolism is a crucial, although partial, mechanism of compensation for ACLY deficiency.
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In Brief
Zhao et al. demonstrate that ACLY deficiency causes upregulation of ACSS2 in proliferating cells in vitro and adipocytes in vivo. Acetate is needed for viability and is used for lipid synthesis and histone acetylation in the absence of ACLY. Proliferation is constrained in ACLY-deficient cells, despite ACSS2 compensation.
INTRODUCTION
Acetyl-coenzyme A (CoA) is a central molecule in cell metabolism, signaling, and epigenetics. It serves crucial roles in energy production, macromolecular biosynthesis, and protein modification (Carrer and Wellen, 2015; Pietrocola et al., 2015) . Within mitochondria, acetyl-CoA is generated from pyruvate by the pyruvate dehydrogenase complex (PDC), as well as from catabolism of fatty acids and amino acids. To enter the tricarboxylic acid (TCA) cycle, acetyl-CoA condenses with oxaloacetate, producing citrate, a reaction catalyzed by citrate synthase. Transfer of acetyl-CoA from mitochondria to the cytosol and nucleus involves the export of citrate and its subsequent cleavage by ATP-citrate lyase (ACLY), generating acetyl-CoA and oxaloacetate. This acetyl-CoA is used for a number of important metabolic functions, including synthesis of fatty acids, cholesterol, and nucleotide sugars such as UDP-N-acetylglucosamine. Acetyl-CoA also serves as the acetyl-group donor for both lysine and N-terminal acetylation (Carrer and Wellen, 2015; Pietrocola et al., 2015) . ACLY plays an important role in regulating histone acetylation levels in diverse mammalian cell types (Covarrubias et al., 2016; Donohoe et al., 2012; Lee et al., 2014; Wellen et al., 2009) .
In addition to ACLY, nuclear-cytosolic acetyl-CoA is produced from acetate by acyl-CoA synthetase short chain family member 2 (ACSS2) (Luong et al., 2000) . Recent studies have revealed an important role for this enzyme in hypoxia and in some cancers Gao et al., 2016; Kamphorst et al., 2014; Mashimo et al., 2014; Schug et al., 2015 Schug et al., , 2016 Yoshii et al., 2009) . Acetate can be produced intracellularly by histone deacetylase reactions or can be imported from the environment (Carrer and Wellen, 2015) . Levels of acetate in circulating blood are rather low, ranging from 50 to 200 mM in humans, although acetate concentrations can increase substantially in certain conditions, such as following alcohol consumption, high-fat feeding, or infection, or in specific locations such as the portal vein (Balmer et al., 2016; Herrmann et al., 1985; Lundquist et al., 1962; Perry et al., 2016; Scheppach et al., 1991; Skutches et al., 1979; Tollinger et al., 1979) . Acetate is also exported by cells under certain conditions, such as low intracellular pH (McBrian et al., 2013) , and thus could potentially be made available for uptake by other cells in the immediate microenvironment. Two additional acetyl-CoA-producing enzymes, the PDC and carnitine acetyltransferase (CrAT), have been reported to be present in the nucleus and to contribute acetyl-CoA for histone acetylation (Madiraju et al., 2009; Sutendra et al., 2014) . The PDC was shown to translocate from mitochondria to the nucleus under certain conditions, such as growth factor stimulation; within the nucleus, the complex is intact and retains the ability to convert pyruvate to acetyl-CoA (Sutendra et al., 2014) . The relative contributions of each of these enzymes to the regulation of histone acetylation and lipid synthesis, as well as the mechanisms of metabolic flexibility between these enzymes, are poorly understood.
Whole-body loss of ACLY is early embryonic lethal, indicating that it serves non-redundant roles during development (Beigneux et al., 2004) . Silencing or inhibition of ACLY suppresses the proliferation of many cancer cell lines and impairs tumor growth Hanai et al., 2012; Hatzivassiliou et al., 2005; Migita et al., 2008; Shah et al., 2016; Zaidi et al., 2012) . Depending on the context, ACLY silencing or inhibition can also promote senescence (Lee et al., 2015) , induce differentiation , or suppress cancer stemness (Hanai et al., 2013) , further pointing to its potential as a target for cancer therapy. Inhibition of ACLY in adult animals and humans is reasonably well tolerated and produces blood lipid-lowering effects (Ballantyne et al., 2013; Gutierrez et al., 2014; Pearce et al., 1998) . Thus, there may be a therapeutic window for ACLY inhibition in treatment of cancer and/or metabolic diseases; although the extent to which cells could leverage other compensatory mechanisms upon reduced ACLY function is not clear.
In this study, we aimed to elucidate two questions: first, does use of glucose-derived carbon for fatty acid synthesis and histone acetylation require ACLY; and second, can cells compensate for ACLY deficiency and, if so, by which mechanisms or pathways? To address these questions, we generated a conditional mouse model of Acly deficiency (Acly f/f mice), as well as immortalized mouse embryonic fibroblast (MEF) cell lines (Acly f/f MEFs). As a complement to these models, we used CRISPR-Cas9 genome editing to delete ACLY from human glioblastoma cells. ACLY deficiency in both MEFs and glioblastoma cells potently impaired proliferation and suppressed histone acetylation levels. Both lipid synthesis and histone acetylation from glucose-derived carbon were severely impaired in ACLY-deficient MEFs. Cells partially compensated for the absence of ACLY by upregulating ACSS2, and ACLY-deficient MEFs became dependent on exogenous acetate for viability. Acetate was used to supply acetyl-CoA for both lipid synthesis and histone acetylation, although global histone acetylation levels remained low unless cells were supplemented with high levels of acetate. ACSS2 upregulation in the absence of ACLY was also observed in vivo upon deletion of Acly from adipocytes in mice. Figure S1B ). To address this, we generated three clonal Acly knockout (KO) cell lines, designated PC7, PC8, and PC9 ( Figure 1A ). ACSS2 was strikingly upregulated in these cell lines ( Figure 1A ). Proliferation in the absence of ACLY was significantly slower in each of the KO cell lines than in the parental Acly f/f cells ( Figure 1B ). We also used CRISPR-Cas9 to delete ACLY from LN229 glioblastoma cells ( Figure 1C ). ACSS2 levels were high at baseline in LN229 cells and only modestly increased with ACLY deletion ( Figure 1C ). However, similar to the ACLY-deficient MEFs, ACLY-deficient LN229 clones exhibited a marked proliferative impairment ( Figure 1D) .
Two of the ACLY-KO clones, PC7 and PC9, were reconstituted with wild-type ACLY (ACLY-WT) or a catalytically inactive ACLY mutant (ACLY-H760A) ( Figures 1E and S1D ). ACLY-WT, but not ACLY-H760A, significantly restored proliferation in the KO clones ( Figures 1F and S1E ). Of note, despite comparable expression upon initial reconstitution (data not shown), ACLY-H760A failed to stably express as highly as ACLY-WT ( Figure S1D ), further pointing to a strong selective advantage for cells expressing catalytically active ACLY. ACSS2 levels were elevated in both the nucleus and cytoplasm of ACLYdeficient cells, and this was reversed upon reconstitution of ACLY-WT ( Figure 1E ).
Next, we inquired whether ACSS2 upregulation was induced by ACLY deletion or whether growing up ACLY-deficient clones selected for those that already had high ACSS2 expression. To test this, we examined the timing of ACSS2 upregulation upon loss of ACLY function. In Acly f/f MEFs, ACSS2 was rapidly upregulated in parallel to loss of ACLY protein following Cre administration ( Figure 1G ). Moreover, treatment of MEFs with an ACLY inhibitor (BMS-303141) led to increased ACSS2 within 96 hr ( Figure 1H ). Thus, we conclude that the loss of ACLY activity induces ACSS2 upregulation.
ACLY-Deficient MEFs Require Use of Exogenous Acetate for Viability
The amount of acetate in the serum used in these experiments was quantified by nuclear magnetic resonance (NMR). Undiluted calf serum (CS) contained $800-900 mM acetate, while acetate was undetectable in dialyzed fetal bovine serum (dFBS) (Figures 2A and S2A) . Given that acetate was also undetectable in DMEM, our standard culture conditions (DMEM + 10% CS) exposed cells to slightly less than 100 mM acetate. ACLY-deficient cells began to die when cultured in the absence of exogenous acetate (DMEM + 10% dFBS) ( Figures 2B-2D) , and adding 100 mM acetate was sufficient to restore viability (Figures 2C and 2E) . No added proliferative benefit was gained by further increasing the amount of acetate supplemented ( Figure 2F ). Additionally, reconstitution of ACLY-WT, but not ACLY-H760A, restored the ability of KO cells to grow in acetate-depleted conditions (Figures 2B and 2E) . To test whether acetyl-CoA production by ACSS2 was required for viability, we used CRISPR-Cas9 to delete Acss2 in Acly f/f MEFs ( Figure S2B ). Little For all panels: **p < 0.01; ***p < 0.001; ****p < 0.0001; n.s., not significant. See also Figure S1 .
to no difference in the proliferation rate was observed upon Acss2 deletion when Acly was intact ( Figure S2C ). However, subsequent deletion of Acly resulted in extensive toxicity ( Figures 2G and S2D) , which was not observed in cells expressing Acss2, confirming that cells rely on ACSS2 for survival in the absence of ACLY.
Physiological Levels of Acetate Support Lipid Synthesis in the Absence of ACLY ACLY deficiency did not alter rates of glucose or glutamine consumption, although lactate and glutamate production were elevated ( Figure 3A) . To confirm the requirement for ACLY for glucose-dependent fatty acid synthesis and test the use of acetate, we set up parallel stable isotope tracer experiments in which Acly f/f , PC9, PC9-ACLY-WT, and PC9-ACLY-H760A cells were incubated for 48 hr either with [U-
13
C]glucose (10 mM) and unlabeled acetate (100 mM) or with [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]acetate (100 mM) and unlabeled glucose (10 mM) ( Figure 3B ). In ACLY-proficient cells, palmitate was strongly labeled from glucose-derived carbon, as expected. In PC9 ACLY-KO cells, labeling of palmitate from 13 C-glucose was nearly abolished; this could be restored by reconstitution of ACLY-WT but not ACLY-H760A ( Figure 3C ). Conversely, a marked increase in use of acetate for fatty acid synthesis was observed in PC9 and PC9-ACLY-H760A cells (legend continued on next page) ( Figure 3D ). We also examined the use of glucose and acetate carbon for synthesis of HMG (hydroxymethylglutaryl)-CoA, an intermediate in the mevalonate pathway and ketone body synthesis. Again, parental and PC9-ACLY-WT cells used glucose-derived carbon for HMG-CoA synthesis ( Figure 3E ). In the absence of ACLY, glucose carbon use for HMG-CoA synthesis was extremely limited ( Figure 3E ); instead, acetate was used ( Figure 3F ). Total levels of HMG-CoA trended slightly lower in the PC9 cells, though this difference was not statistically significant ( Figure 3G ). The data thus show that, in MEFs, glucose-dependent synthesis of fatty acids and HMG-CoA is nearly completely dependent on ACLY, and a physiological level of acetate can at least partially support lipid synthesis in its absence.
ACLY Is the Primary Supplier of Acetyl-CoA for Maintaining Global Histone Acetylation
Histone acetylation is another major fate of nuclear-cytosolic acetyl-CoA. Consistent with previous data using RNAi-mediated ACLY silencing (Lee et al., 2014; Wellen et al., 2009) , global levels of histone acetylation were strikingly reduced upon genetic deletion of Acly, despite increased ACSS2. Moreover, although 100 mM acetate was sufficient to restore survival in dFBScultured KO cells, it failed to rescue histone acetylation levels. However, incubating cells with a high level of acetate (1 mM) markedly increased histone acetylation levels in KO cells (Figure 4A) . Reciprocally, histone acetylation levels were low in WT MEFs when cultured in 1 mM glucose and increased with greater glucose concentrations. In KO cells, histone acetylation levels were low at all concentrations of glucose tested, up to 25 mM ( Figure S3A ). Reconstitution of PC9 cells with ACLY-WT but not, ACLY-H760A, restored histone acetylation levels to those in the parental cells ( Figure 4A ). To determine the respective use of glucose-and acetatederived carbon for histone acetylation in each of the MEF cell lines, we conducted stable isotope tracer experiments under three conditions: (1) [U-
13 C]glucose (10 mM) and unlabeled acetate (100 mM), (2) physiological [1,2-13 C]acetate (100 mM) and unlabeled glucose (10 mM), or (3) high [1,2-13 C]acetate
(1 mM) and unlabeled glucose (10 mM) ( Figure S3B ). In condition 1, histone acetyl groups were strongly labeled from 13 C-glucose in Acly f/f and PC9-ACLY-WT cells (Figures 4B, 4E, and S3C) . In PC9 and PC9-ACLY-H760A cells, labeling of histone acetyl groups from glucose carbon was severely compromised (Figures 4B, 4E, and S3C) . Moreover, aligning with western blot data, total levels of histone acetylation were lower in cells lacking functional ACLY ( Figure 4E ). Thus, the data indicate that ACLY is required for the majority of glucose-dependent histone acetylation. In cells lacking functional ACLY (PC9 and PC9-ACLY-H760A), 100 mM acetate contributed carbon to histone acetylation with $40%-60% of the acetyl groups derived from acetate after 24-hr labeling ( Figure 4C ), but total acetylation remained low ( Figures 4F and S3D ). In 1 mM 13 C-acetate, total histone acetylation levels rose (Figures 4G and S3E) , consistent with western blot data, and acetate carbon constituted the majority of histone acetyl groups ( Figure 4D ). These data indicate that ACLY is the dominant supplier of acetyl-CoA for histone acetylation in standard, nutrient-rich conditions and that, in its absence, cells can use acetate to supply acetyl-CoA for histone acetylation, although high exogenous acetate availability is needed to bring histone acetylation up to levels matching those of ACLY-proficient cells. Of note, high acetate did not produce a corresponding rescue of proliferation ( Figure 2F ). Thus, while ACLY-deficient cells exhibit both slower proliferation and lower histone acetylation levels, histone acetylation can be raised with high acetate without restoration of normal rates of proliferation, supporting the notion that metabolism regulates histone acetylation at least partially independently of proliferation. We previously defined acetyl-CoA-responsive gene sets in LN229 glioblastoma cells (Lee et al., 2014) . Cell-cycle-and DNA-replication-related genes were enriched among those genes that were suppressed in low glucose and increased by both glucose and acetate, although only glucose impacted doubling time (Lee et al., 2014) . As observed in MEFs, ACLY deletion in LN229 cells abolished glucose-dependent regulation of global histone acetylation ( Figure S4A ). Acetate supplementation increased histone acetylation in ACLY null LN229 cells in a dose-dependent manner ( Figure S4A ). Consistently, the ability of glucose to promote expression of proliferation-related genes (E2F2, MCM10, and SKP2) was potently inhibited in ACLY-deficient cells. Expression of these genes exhibited dose-dependent rescue by acetate ( Figure S4B ), correlating with global histone acetylation levels, despite the lack of a proliferation rescue (Figure S4C ). In addition, we were surprised to find that whole-cell acetyl-CoA levels were minimally impacted in ACLY-KO as compared to WT LN299 cells in high-glucose conditions ( Figure S4D ).
Acetyl-CoA Levels Are Maintained by Acetate in ACLY-Deficient Cells
In prior studies, global histone acetylation levels have tracked closely with cellular acetyl-CoA levels (Cai et al., 2011; Cluntun et al., 2015; Lee et al., 2014) . It was, therefore, unexpected to find these uncoupled in ACLY-KO LN229 cells ( Figure S4D ). We further explored this in ACLY-KO MEFs and found that acetyl-CoA levels were significantly higher in the KO cells than in the WT Acly f/f cells when cultured in 10 mM glucose and 100 mM acetate ( Figure 5A ). These data suggested either that mitochondrial acetyl-CoA, which is inaccessible for histone acetylation (Takahashi et al., 2006) , is elevated in ACLY-KO cells or that ACSS2 compensation allows plentiful nuclear-cytosolic acetyl-CoA production from acetate but that this acetatederived acetyl-CoA is used less effectively than glucose-derived acetyl-CoA for histone acetylation. We reasoned that mitochondrial and extra-mitochondrial acetyl-CoA pools in ACLY KO cells (legend continued on next page) could be distinguished based on whether whole-cell acetyl-CoA is derived from glucose or from acetate ( Figure 5B ). This is because, in the absence of ACLY, glucose carbon does not meaningfully contribute to nuclear-cytosolic acetyl-CoA, as determined by its minimal use for either lipid synthesis or histone acetylation (Figures 3 and 4) . Within mitochondria, both glucose (via PDC) and acetate (via mitochondrial acetyl-CoA synthetases) can be used to generate acetyl-CoA for citrate synthesis. However, as assessed by enrichment of citrate and malate, acetate contributes minimally to mitochondrial metabolism in both WT and KO cells, while glucose is oxidized in both cell lines under these conditions (albeit to a somewhat lesser extent in KO cells) ( Figures 5C, 5D , S5A, and S5B). These data suggest that, in ACLY-KO cells, any glucose-derived acetyl-CoA is mitochondrial, whereas acetate-derived acetyl-CoA is predominantly nuclear cytosolic ( Figure 5B ). Figure 3D ), $20% of the acetyl-CoA pool was enriched from 13 C-acetate ( Figures 5E and 5F ), further hinting at differential partitioning of acetate-and glucose-derived acetyl-CoA. In contrast, in the PC9 ACLY-KO cells, acetyl-CoA was minimally labeled from glucose, and $80% of the acetyl-CoA pool was labeled from acetate after 6 hr ( Figure 5E ). Malonyl-CoA, but not succinyl-CoA, was also strongly enriched from 13 C-acetate in PC9 cells (Figures 5F and 5G) . In sum, these data indicate that acetate is the major source of acetyl-CoA in the absence of ACLY, and it appears to predominantly supply the extra-mitochondrial pool.
A second implication of these data is that, at least in KO cells, the mitochondrial acetyl-CoA pool is likely quite low in comparison to the extra-mitochondrial pool, since acetyl-CoA is minimally labeled from glucose-derived carbon. A large difference in relative acetyl-CoA pool size can explain the apparently paradoxical finding that, in KO cells, citrate is labeled from glucose, despite minimal acetyl-CoA enrichment ( Figures 5C and 5E ). This interpretation is consistent with findings from a recent study of the mitochondrial metabolome, which found that matrix acetyl-CoA levels are very low unless complex I is inhibited, which increases the NADH/NAD ratio, reducing the activity of citrate synthase . Notably, another implication of this result is that a much larger nuclear-cytosolic acetyl-CoA pool in cultured cells would explain why whole-cell acetyl-CoA measurements in ACLY-proficient cells correlate closely with histone acetylation levels (Cluntun et al., 2015; Lee et al., 2014) .
Together, these data indicate that acetate carbon is used to supply acetyl-CoA for nuclear and cytosolic processes in the absence of ACLY. Nevertheless, histone acetylation levels remain low in the absence of ACLY unless a high level of acetate is supplied, and proliferation remains constrained even in the presence of high acetate. Thus ACSS2 is a key, but partial, mechanism of compensation for ACLY deficiency.
ACSS2 Is Upregulated In Vivo upon Deletion of Acly from Adipocytes
Finally, we sought to determine whether ACSS2 is upregulated upon loss of ACLY in vivo. Glucose uptake and glucose-dependent lipid synthesis in adipocytes are closely associated with insulin sensitivity and systemic metabolic homeostasis (Herman and Kahn, 2006; Herman et al., 2012) . Moreover, our prior work implicated ACLY in regulating histone acetylation levels and expression of key genes in glucose metabolism, such as Glut4, in 3T3-L1 adipocytes (Wellen et al., 2009 ). To interrogate the role of adipocyte ACLY in vivo, we bred Acly f/f mice to Adiponectin-Cre transgenic mice, which express Cre specifically in adipocytes (Lee et al., 2013) . ACSS2 was upregulated in SWAT and VWAT upon deletion of Acly ( Figures 6A and 6B ). In VWAT, ACSS2 upregulation was more apparent at the protein level than the mRNA level ( Figures 6A and 6B ). Fatty acid synthase (FASN) protein levels were also elevated in the absence of ACLY, particularly in SWAT ( Figure 6A ). Lipid droplets formed normally in Acly FATÀ/À adipocytes; in VWAT, adipocytes were larger than in WT mice, while in SWAT, adipocyte lipid droplet size was comparable between genotypes ( Figure 6C ). Body weight was indistinguishable between WT and Acly FatÀ/À mice fed a regular chow diet ( Figure 6D ). However, overall gene expression patterns were altered, with lower expression of adipocyte genes such as Glut4 in the Acly FATÀ/À mice ( Figure 6E ).
Adipocyte Acetyl-CoA and Lipid Metabolism Is Altered in the Absence of ACLY These data suggested that acetate metabolism might, at least partially, compensate for ACLY deficiency in adipocytes in vivo. Similar to that observed in MEFs, acetyl-CoA levels were higher CS), dFBS medium (DMEM + 10% dFBS), +100 mM acetate medium (DMEM + 10% dFBS + 100 mM sodium acetate), and +1 mM acetate medium (DMEM + 10% dFBS + 1 mM sodium acetate) for 48 hr. (legend continued on next page) (Figures 7B-7D) .
Next, we investigated the extent to which de novo synthesized fatty acids were present in adipose tissue in the absence of ACLY. To capture rates of de novo lipogenesis (DNL) in vivo, D 2 O was administered to mice via a bolus injection and subsequent addition to drinking water for 3 weeks. At the conclusion of labeling VWAT, SWAT, and liver were collected, and total (saponified) fatty acids from each were analyzed by gas chromatography-mass spectrometry (GC-MS). Plasma D 2 O enrichment was confirmed to be equivalent between genotypes ( Figure S6A ). In both VWAT and SWAT, abundance of the saturated fatty acids palmitic acid (C16:0) and stearic acid (C18:0) was significantly reduced ( Figures S6B and S6C) . Conversely, monounsaturated fatty acids, oleic acid (C18:1n9), and palmitoleic acid (C16:1n7), as well as the essential fatty acid linoleic acid (C18:2n6), were elevated in SWAT from Acly FATÀ/À mice (Figure S6B) . A slight reduction in palmitic acid was also observed in liver ( Figure S6D ). Fractional enrichment of fatty acids was not significantly different in VWAT between genotypes, although SWAT exhibited a moderate reduction in palmitic acid fractional synthesis ( Figures S6E and S6F ). Fractional synthesis was not different between genotypes in the liver, except for a small reduction for palmitoleic acid ( Figure S6G ).
The relative quantities of de novo synthesized fatty acids present in each tissue were calculated using plasma D 2 O enrichment, fatty acid labeling, and abundance. Notably, DNL-derived fatty acids present in WAT may be synthesized in adipocytes or produced in the liver and transported to fat. In the SWAT of Acly FATÀ/À mice, total de novo synthesized palmitic acid and stearic acid were significantly reduced ( Figure 7E ). In contrast, no significant differences in the quantities of DNL-generated fatty acids were detected between Acly FATÀ/À and Acly f/f mice in VWAT ( Figure 7F ). Liver DNL was largely unchanged by adipocyte ACLY deficiency, although a slight reduction in palmitic acid synthesis was observed ( Figure 7G ). Since DNL-derived fatty acids were reduced in SWAT of Acly FATÀ/À mice, this depot may maintain lipid droplet size through greater storage of diet-derived fatty acids, as suggested by elevated levels of linoleic acid ( Figure S6B ).
Histone acetylation levels were also analyzed. Despite ACSS2 upregulation and elevated acetyl-CoA levels, H3K9ac and H3K23ac were significantly lower, and H3K18ac trended lower, in the SWAT of Acly FATÀ/À mice ( Figure 7H ). Interestingly, this difference was not observed in VWAT, suggesting that acetate compensation for ACLY deficiency may be more complete in this depot or that other factors are dominant in determining histone acetylation levels ( Figure 7I ). No differences in histone H3 acetylation were detected in the liver ( Figure 7J) . Altogether, the data suggest that, in vivo, adipocytes lacking ACLY partially compensate by engaging acetate metabolism.
DISCUSSION
The findings of this study demonstrate that ACLY is required for the vast majority of glucose-dependent fatty acid syntheses and histone acetylations under standard culture conditions and that ACSS2 upregulation and use of acetate carbon is a major mechanism of compensation for ACLY deficiency. Additionally, despite ACSS2 upregulation and higher acetyl-CoA levels, ACLY deficiency results in lower overall histone acetylation levels, slower proliferation, and altered gene expression patterns. The data suggest that ACLY and ACSS2 likely play distinct roles in the regulation of histone acetylation and gene expression but also indicate that the potential for metabolic compensation from acetate should be considered if ACLY is pursued as a therapeutic target.
From a clinical perspective, prior study of PET (positron emission tomography) imaging in human hepatocellular carcinoma patients using 11 C-acetate and F-FDG uptake were more proliferative (Yun et al., 2009) . These data support the concept that mammalian cells-cancer cells, in particular-possess an intrinsic flexibility in their ability to acquire acetyl-CoA from different sources to adjust to changing metabolic environments in vivo. Further elucidation of the mechanisms connecting ACLY and ACSS2, as well as the differential phenotypes observed downstream of their activity, could point toward synthetic lethal strategies for cancer therapy or improved tumor imaging protocols.
In considering the roles of these enzymes in normal physiology, given the importance of GLUT4-dependent glucose uptake and glucose-dependent fatty acid synthesis for systemic metabolic homeostasis (Herman and Kahn, 2006; Herman et al., 2012) , deletion of Acly in adipocytes results in a surprisingly mild phenotype, with no overt metabolic dysfunction observed for mixed-background mice on a regular chow diet. Nevertheless, larger adipocytes and reduced expression of genes, such as Glut4, observed in this model are also characteristic of obesity and are associated with poorer metabolic function. This suggests that Acly FATÀ/À mice may be more susceptible to For all panels: *p < 0.05; **p < 0.01.
(legend on next page) metabolic dysfunction when nutritionally stressed, for example, with high fructose feeding. Another interesting question is whether these mice will exhibit exacerbated metabolic phenotypes under conditions that alter acetate availability in the bloodstream, such as ethanol consumption or antibiotic treatment.
The differential impact of ACLY on SWAT and VWAT also warrants further investigation. It is not clear why SWAT, but not VWAT, exhibits reduced histone acetylation and de novo fatty acid synthesis, despite evidence for compensatory mechanisms such as FASN upregulation. One possible explanation relates to an overall greater fraction of fatty acids that are de novo synthesized in SWAT, as compared to VWAT ( Figures  S6E and S6F) , placing a greater demand for acetyl-CoA. Potentially, in a tissue with a lower DNL rate, acetate may be more readily able to compensate in both DNL and histone acetylation. Distribution of fatty acids in Acly FATÀ/À WAT depots is also altered; SWAT, in particular, exhibits increased levels of monounsaturated and essential fatty acids ( Figure S6B ). Palmitoleate, which has been implicated as an insulin-sensitizing lipokine (Cao et al., 2008) , is elevated in ACLY-deficient SWAT, raising questions about how altered levels of bioactive lipid species in the absence of ACLY may influence metabolic phenotypes. More mechanistic work is also clearly needed to elucidate the relationship between ACLY and gene regulation. The relationship between global histone acetylation and gene expression is not entirely consistent between VWAT and SWAT, possibly reflecting gene regulatory mechanisms that are specific to ACLY. A noteworthy observation in this study is that acetyl-CoA and histone acetylation levels appear to become uncoupled in the absence of ACLY, suggesting that acetate-derived acetylCoA may not be efficiently used for histone acetylation. Several possible mechanisms could account for this. First, it may be that, in MEFs, an insufficient amount of ACSS2 is present in the nucleus to efficiently drive histone acetylation. ACSS2 has been found to localize prominently to the nucleus in some conditions (Chen et al., 2015; Comerford et al., 2014; Xu et al., 2014) ; thus, investigation of whether acetate more readily contributes to overall histone acetylation levels in these contexts will be informative. However, potentially arguing against this possibility, hypoxia promotes ACSS2 nuclear localization (Xu et al., 2014 ); yet, although acetate does regulate histone acetylation in hypoxic cells, a high level of acetate ($2.5 mM) is required (Gao et al., 2016) . A second possibility is that, within the nucleus, acetyl-CoA producing enzymes are channeled, compartmentalized into niches, or sequestered with particular binding partners. Through such a mechanism, acetylation of specific proteins may be regulated not only by the relevant acetyltransferase but also by a specific acetyl-CoA-producing enzyme. Consistent with this possibility, acetylation of HIF2a was shown to be exclusively dependent on ACSS2 as a source of acetyl-CoA (Chen et al., 2015; Xu et al., 2014) . A third possibility is that ACLY-deficient conditions may result in altered lysine acetyltransferase (KAT) or HDAC (histone deacetylase) activity. Finally, a fourth possibility is that lower use of acetyl-CoA for histone acetylation could be a feature of slow proliferation in the absence of ACLY (i.e., secondary to the proliferation defect). However, prior findings that histone acetylation is sensitive to glucose availability over a range that did not impact proliferation (Lee et al., 2014) and that the TCA cycle (which supplies ACLY substrate citrate) and mitochondrial membrane potential have distinct and separate roles in regulating histone acetylation and proliferation, respectively (Martí-nez-Reyes et al., 2016) , as well as data in the present article showing that histone acetylation can be boosted by high acetate without a corresponding rescue of proliferation, argue against this as a sole explanation. Nevertheless, elucidation of the mechanisms that constrain proliferation in the absence of ACLY could help to definitively address this.
Investigating these possibilities will illuminate whether cells possess mechanisms to differentially detect ACLY-generated versus ACSS2-generated acetyl-CoA as well as define the functional relationship between histone acetylation levels and cellular functions and phenotypes. Given that ACLY dominates in nutrient-and oxygen-replete conditions, whereas ACSS2 becomes important in nutrient-and oxygen-poor conditions (Gao et al., 2016; Schug et al., 2015) , having mechanisms such as different acetylation substrates to distinguish between acetylCoA produced by each enzyme could be advantageous to cells. For example, such mechanisms could potentially cue cells to grow when ACLY serves as the acetyl-CoA source and to mediate adaptive responses when ACSS2 is the primary acetyl-CoA source. The roles of these enzymes in gene regulation appear to be complex, and in-depth analysis of the respective roles of ACLY and ACSS2 in genome-wide histone acetylation and acetylation of other protein substrates is needed to begin addressing these questions.
Recent work has shown that the PDC is present in the nucleus and is able to convert pyruvate to acetyl-CoA for use in histone acetylation (Sutendra et al., 2014) , raising the question of how the findings of the present study can be aligned with the described role of nuclear PDC. We suggest two potential models that are consistent both with our data and with a role for nuclear PDC in histone acetylation. In the first model, ACLY is the primary acetyl-CoA producer for regulation of global levels of histone acetylation, while PDC (and, potentially, other nuclear acetyl-CoA sources such as CrAT) could participate in mediating histone acetylation at specific target genes but not globally. A recent report that PDC forms a complex with PKM2, p300, and the arylhydrocarbon receptor (AhR) to facilitate histone acetylation at AhR target genes is consistent with such a possibility (Matsuda et al., 2015) . In the second model, the role of ACLY in glucose-dependent histone acetylation regulation could be context dependent, with a larger role for PDC emerging in certain conditions or cell types. This possibility is supported by observations that PDC nuclear translocation is stimulated by conditions such as growth factor stimulation and mitochondrial stress (Sutendra et al., 2014) . Further investigation will be needed to evaluate these models.
In sum, this study points to a crucial interplay between glucose and acetate metabolism to supply the nuclear-cytosolic acetylCoA pool for fatty acid synthesis and histone acetylation. At the same time, it shows that, despite compensatory mechanisms, ACLY is required for optimal proliferation, and simply increasing nuclear-cytosolic acetyl-CoA production is insufficient to fully replace ACLY. This could point to the importance of ACLY's other product, oxaloacetate; a build-up of ACLY's substrate citrate; deficiencies in anapleurosis and/or mitochondrial function upon loss of a major catapleurotic pathway; or a signaling mechanism that is specific to ACLY. Clearly, more work is needed both to understand the mechanisms through which ACLY facilitates cell proliferation and to further define the ways that cells partition and use acetyl-CoA produced by different enzymes. The findings of this study raise a number of important questions for future investigation, as discussed earlier.
They also clarify the importance of ACLY in glucose-dependent acetyl-CoA production outside of mitochondria and provide key insights into the mechanisms of metabolic flexibility used for production of nuclear-cytosolic acetyl-CoA. Understanding these compensatory mechanisms will be important to consider for therapeutic targeting of acetyl-CoA metabolic pathways. Cell Culture and Proliferation Assays MEFs (generation described in the Supplemental Information) were cultured in DMEM (GIBCO) supplemented with 10% Cosmic Calf Serum (CS) (HyClone, SH30087.03, lot number AXA30096). LN229 cells were cultured in RPMI 1640 medium (GIBCO) supplemented with 10% CS (HyClone SH30087.03, lot number AXA30096) and 2 mM L-glutamine. For experiments using dFBS, cells were cultured in glucose-free DMEM + 10% dFBS (GIBCO 26400044), with indicated concentrations of glucose and sodium acetate added. For proliferation assays, cells were plated in triplicate at the indicated density and allowed to adhere overnight. Culture medium was changed the following day, and cells were allowed to proliferate until the indicated days following plating. Cells were collected and counted on a hemocytometer. Cell lines used for viral production included Phoenix E and HEK293T cells, which were purchased from ATCC. Cells were cultured in DMEM + 10% CS and used at low passage. All cell lines were routinely monitored and confirmed to be free of mycoplasma.
EXPERIMENTAL PROCEDURES

Generation of
Acyl-CoA Quantification and Isotopologue Analysis
Acyl-CoA species were extracted in 1 mL 10% (w/v) trichloroacetic acid (Sigma-Aldrich, catalog #T6399). Isotopologue enrichment analysis to quantify the incorporation of 10 mM [U-13 C]glucose and 100 mM [U-13 C]acetate into acyl-CoA thioesters was performed by liquid chromatograpy-mass spectrometry/high-resolution mass spectrometry (LC-MS/HRMS). For quantitation, internal standards containing [ 13 C 3 15 N 1 ]-labeled acyl-CoAs generated in pan6-deficient yeast culture (Snyder et al., 2015) were added to each sample in equal amounts. Samples were analyzed by an Ultimate 3000 autosampler coupled to a Thermo Q Exactive Plus instrument in positive electrospray ionization (ESI) mode using the settings described previously (Frey et al., 2016) . A more detailed method can be found in the Supplemental Information.
Statistics
Student's two-tailed t tests (two-sample equal variance, two-tailed distribution) were used for analyses directly comparing two datasets except tissue gene expression and acyl-CoA datasets (Figures 6 and 7) , for which Welch's t test was used. Significance was defined as follows: *p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 0.0001. Please also see the Supplemental Experimental Procedures. 
SUPPLEMENTAL INFORMATION
